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Abstract
Background: Recombinant human erythropoietin (rHuEpo) can improve human performance and is therefore
frequently abused by athletes. As a result, the World Anti-Doping Agency (WADA) introduced the Athlete Biological
Passport (ABP) as an indirect method to detect blood doping. Despite this progress, challenges remain to detect
blood manipulations such as the use of microdoses of rHuEpo.
Methods: Forty-five whole-blood transcriptional markers of rHuEpo previously derived from a high-dose rHuEpo
administration trial were used to assess whether microdoses of rHuEpo could be detected in 14 trained subjects
and whether these markers may be confounded by exercise (n = 14 trained subjects) and altitude training (n = 21
elite runners and n = 4 elite rowers, respectively). Differential gene expression analysis was carried out following
normalisation and significance declared following application of a 5% false discovery rate (FDR) and a 1.5 fold-
change. Adaptive model analysis was also applied to incorporate these markers for the detection of rHuEpo.
Results: ALAS2, BCL2L1, DCAF12, EPB42, GMPR, SELENBP1, SLC4A1, TMOD1 and TRIM58 were differentially expressed
during and throughout the post phase of microdose rHuEpo administration. The CD247 and TRIM58 genes were
significantly up- and down-regulated, respectively, immediately following exercise when compared with the
baseline both before and after rHuEpo/placebo. No significant gene expression changes were found 30 min after
exercise in either rHuEpo or placebo groups. ALAS2, BCL2L1, DCAF12, SLC4A1, TMOD1 and TRIM58 tended to be
significantly expressed in the elite runners ten days after arriving at altitude and one week after returning from
altitude (FDR > 0.059, fold-change varying from 1.39 to 1.63). Following application of the adaptive model, 15 genes
showed a high sensitivity (≥ 93%) and specificity (≥ 71%), with BCL2L1 and CSDA having the highest sensitivity
(93%) and specificity (93%).
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Conclusions: Current results provide further evidence that transcriptional biomarkers can strengthen the ABP
approach by significantly prolonging the detection window and improving the sensitivity and specificity of blood
doping detection. Further studies are required to confirm, and if necessary, integrate the confounding effects of
altitude training on blood doping.
Keywords: Recombinant human erythropoietin, Whole blood, Transcriptome, Altitude, Exercise, Athlete
biological passport
Background
The performance-enhancing drug recombinant human
erythropoietin (rHuEpo) stimulates red blood cell
production and although the World Anti-Doping
Agency (WADA) prohibits its use, is frequently
abused by athletes. The early anti-doping approach
was to set an upper limit for haemoglobin and haem-
atocrit levels in an attempt to discover rHuEpo abuse
[1]. The first direct analytical procedure to detect
rHuEpo was introduced in 2000 and exploited the dif-
ferences in the charge profiling of endogenously and
exogenously produced Epo in urine by isoeletric
focusing (IEF) [2]. The main limitations of this direct
approach are a variable and short detection window
and low sensitivity [3]. There is now an improved
direct analytical test to detect rHuEpo using sarcosyl
polyacrylamide gel electrophoresis (SAR-PAGE, a
modified sodium dodecyl sulfate polyacrylamide gel
electrophoresis) with increased discriminatory capacity
compared to IEF and detection window of 24 to 85 h
using blood and urine samples [4]. According to the
WADA technical document (i.e. TD2014EPO), SAR-
PAGE is currently recommended for rHuEpo detec-
tion in both the initial and confirmation testing
procedures [5]. Despite these advances, important
limitations in detection of the direct approach have
prompted a paradigm shift to the indirect
identification of the effect of the prohibited method
and/or substance.
One of the initial indirect methods involved the use of
altered haematological markers such as reticulocyte
haematocrit, haematocrit and percent macrocytes for the
detection of current and recent rHuEpo intake using the
ON- and OFF-statistical models, respectively [6]. This
further advance culminated in the development of the
Athlete Biological Passport (ABP) [1], introduced in
2009 by WADA. The ABP monitors changes in the
blood matrix of an individual over time using Bayesian
inference techniques to establish an individual’s haem-
atological profile that can reveal evidence of doping, not
confined only to rHuEpo but also other forms of blood
manipulation [7]. The stability of the ABP haemato-
logical parameters is limited to 48 h for reticulocytes
and 72 h for haemoglobin from blood collection to
analysis when samples are handled at 4 °C and a limit of
36 h has been recommended by WADA for improved
analytical quality [8]. A particular advantage of the ABP
approach is the incorporation of other evidence of
doping, such as longitudinal performance data,
additional biomarkers yet to be discovered and validated
and other nonanalytical evidence [1]. Despite this signifi-
cant advance, the detection of rHuEpo and blood doping
in general, using the current ABP approach, remains
unsatisfactory [9, 10]. For example, the application of
the ABP failed to reveal any evidence of rHuEpo micro-
dosing (i.e. 20–30 IU∙kg−1 body mass rHuEpo twice
weekly for 8 weeks) in 10 healthy male subjects [11]. In
addition, the haematological parameters of the ABP may
be confounded with factors such as altitude exposure,
since hypoxia may affect the blood variables and vascular
volumes [12, 13]. Notwithstanding these limitations, the
addition of other biomarkers to the ABP is envisaged to
improve the sensitivity and specificity of the ABP model,
and therefore substantially enhancing future doping
detection strategies [1, 14, 15].
Current advances in omics technologies permit a
global transcriptional, translational or epigenomic
feature of a cell, tissue or organism under altered physio-
logical or developmental conditions to be investigated.
For example, a state-of-the-art omics approach has been
successfully applied to epidemic diseases (e.g. [16, 17])
and cancer diagnosis [18]. Undoubtedly, the application
of omics to the field of anti-doping will help reveal
potential doping biomarkers. In a study by Varlet-Marie
et al., the gene expression profile in response to
darbepoetin alpha was determined using the serial ana-
lysis of gene expression (SAGE) by pooling whole-blood
samples from 14 healthy, active subjects (50% male) into
three SAGE libraries (before, during and after adminis-
tration) [19]. The authors then confirmed the differential
expression of 95 genes identified using SAGE in two
well-trained male athletes by qPCR [19]. Five genes
remained significantly expressed following a further high
dose and microdose rHuEpo treatment in these athletes
based on a fold change of 1.5 and a false discovery rate
(FDR) of 0% [19]. This initial promise of improved
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discriminatory potential of the transcriptomic bio-
markers to detecting doping, encouraged a number of
other attempts to investigate the global gene expres-
sion patterns in whole blood or lymphocytes for the
detection of testosterone, anabolic steroids, recombin-
ant human growth hormone, gene doping, blood
transfusions and rHuEpo (see review [14]). It should
be noted that samples are often collected for anti-
doping purposes at sporting or training venues after
intense exercise [20] and prior intense exercise train-
ing has been reported to have significant impact on
gene expression profiles of peripheral blood mono-
nuclear cells [21] and white blood cells [22]. We pre-
viously carried out whole-blood gene expression
profiling using a microarray-based approach to detect
rHuEpo doping (i.e. 50 IU∙kg−1 body mass every two
days for 4 weeks). Briefly, 34 of 45 selected genes
from two independent groups following the micro-
array analysis were validated using a different quanti-
fication platform [23]. The limitations of this study
were the absence of a control/placebo group and the
now out-dated rHuEpo dosing regimen involving near
clinical doses of rHuEpo as opposed to the more
commonly used strategy involving rHuEpo microdos-
ing [23]. With these limitations in mind, the aims of
the present study were to investigate 1) whether the
previously identified 45 transcriptional markers could
detect rHuEpo microdosing in a randomised, double-
blind, placebo-controlled cross-over study; and 2)
whether these gene responses differ among rHuEpo
microdosing and potential confounders such as
strenuous exercise training and moderate altitude
exposure.
Methods
Forty-five candidate transcripts and five reference genes
identified from the whole-blood transcriptome profiling
in subjects administered with 50 IU∙kg−1 body mass of
rHuEpo for 4 weeks (i.e. the rHuEpo high-dose study,
see Additional file 1) [23] were interrogated in subjects
participating in the rHuEpo microdose study and the
rHuEpo confounders studies involving exercise and alti-
tude training (Fig.1).
Study design
Microdose study (MDS)
Fourteen endurance-trained healthy males (mean ± stand-
ard deviation (SD); age: 29.9 ± 4 yrs., height: 178.8 ± 4.5
cm, maximal aerobic capacity (V
:
O2max): 55.3 ± 4.7 ml∙kg
−1∙min−1) at sea-level (Glasgow, Scotland) not involved in
competition during the study period participated in a ran-
domised, double-blind, placebo-controlled crossover
microdose rHuEpo study. Written informed consents
were obtained from all participants. The study was
approved by the University of Glasgow Ethics Committee
(Scotland, UK). The subjects received 20–40 IU∙kg−1 body
mass subcutaneous injections of rHuEpo (NeoRecormon,
Roche, Welwyn Garden City, UK) or equivalent saline
(NaCl 0.9%, Baymed Healthcare Limited, Glasgow, UK;
placebo injection) twice a week for 7 weeks (Fig. 2). All
subjects received daily iron tablets providing approxi-
mately 105 mg of elemental iron derived from 350 mg of
dried ferrous sulphate (Almus, Barnstaple, UK), while
lactose (Minerals-Water, Purfleet, UK) substituted daily
iron during the placebo trial.
All subjects were also subjected to a modified Wingate
test comprising of 10 sprints of 10 s at baseline and
during the week after the last rHuEpo or placebo injec-
tions (Fig. 2; performance data not included here).
Specifically, after a 5-min cycling warm-up at 100 W,
with a flat-out sprint at 3 min for 5 s, followed by a 5-
min rest [24], each subject performed a series of ten,
maximal effort 10 s sprints, separated by a 50 s rest
interval. The subject then underwent 10 min of active
recovery at 100 W followed by 110 min of rest.
Altitude training study (ATS)
Twenty-one elite endurance runners (12 males and 9
females) were recruited (mean ± SD; age: 23.2 ± 2 yrs.,
height: 175.3 ± 8.5 cm, body mass index (BMI): 19.7 ±
1.2 kg∙m−2). Informed, written consents were obtained
from all participants. This study was approved by the Eth-
ics Committee of the University of Brighton (England,
UK). Participants were randomly assigned into an altitude
group (n = 12; trained at Sierra Nevada, Spain, 2320 m,
for approximately 2–3 weeks, with one participant return-
ing from altitude after 8 days and another after 28 days)
High-Dose Study (HDS)
SCO (n = 18), KEN (n = 20)
Micro-Dose Study (MDS)
Physically active Caucasians 
(n=14); also subjected to strenuous 
exercise
Altitude Training Study (ATS)
Elite Caucasian runners (n = 21)  
Elite Caucasian rowers (n = 4)
Illumina HT array
SCO (n = 18), KEN (n = 18)
Quantigene Plex Assay
SCO (n = 18), KEN (n = 20)
34 validated transcripts out of 45
Quantigene Plex Assay
Fig. 1 A simplified diagram of the study flow specifying sample size and analytical platforms used. SCO: Scottish cohort in the HDS. KEN: Kenyan
cohort in the HDS
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and a control group (n = 9; trained at sea level for approxi-
mately 2 weeks). Both groups followed the same training
programme in preparation for a major international
athletics competition.
Four elite male rowers were also recruited (mean ± SD;
age: 25.3 ± 3.6 yrs., height: 193.3 ± 3.6 cm, BMI: 26.3 ±
1.2 kg∙m−2 and V
:
O2max: 63.8 ± 4.3 ml∙kg
−1∙min−1). These
athletes underwent 2-week of altitude training (Santa
Caterina di Valfurva, Italy, 1850 m) in preparation for an
international competition. Prior to and after the altitude
exposure, these athletes remained in a hypoxic chamber/
altitude room (16 m2; excluding training and for meals)
set to an oxygen concentration equivalent to 2500 m for
5 days. Informed and written consent was obtained from
all participants and approved by the Ethics Committee
of the University of Glasgow (Scotland, UK).
Blood sampling and RNA extraction
In the MDS, whole blood samples were collected in trip-
licate at baseline (approximately day −14, −7 and 0) and
then once a week for 7 weeks during rHuEpo adminis-
tration (approximately day 3, 10, 17, 24, 31, 38 and 45)
and for 3 weeks post rHuEpo administration (approxi-
mately day 52, 59 and 66) (Fig. 2). Whole blood samples
were also obtained before, immediately after the 10
sprints and 30 min after the last sprint following the
modified Wingate test both at baseline and after the last
rHuEpo or placebo injections (Fig. 2). In the ATS, whole
blood samples were collected from the elite runners at
baseline (approximately day −14), during (approximately
day 10), 48-h-, 1-week-, 2-week- and 4-week-post alti-
tude exposure, respectively. Samples were also obtained
from the control group of elite runners at baseline
(approximately day −14), 2-week- and 4-week-post the
sea-level training period. Whole blood samples were col-
lected from the elite rowers at baseline (day −14 and
−10), during (day 5 and 22) and post (day 29, 33 and 39)
simulated and natural altitude exposure (days are rela-
tive to the first day of the simulated altitude). For all
studies, 3 mL whole blood sample was collected using
the Tempus™ Blood RNA tube (Life Technologies,
Carlsbad, CA, USA) and mixed vigorously with 6 mL
stabilising reagent immediately after collection. The
whole sample was incubated at room temperature for
approximately 3 h and then stored at −20 °C before
subsequent analysis. Three-millilitre whole blood was
collected in K3EDTA tubes (Greiner Bio-One Ltd.,
Stonehouse, UK) for haematology analysis, and the
whole blood was mixed thoroughly with the tube
additive by gently inverting the tube 5–10 times as per
the manufacturer’s instructions.
Total RNA was isolated from the whole blood
collected using Tempus tubes according to the manufac-
turer’s instructions (Tempus™ Spin RNA Isolation Kit,
Life Technologies, Carlsbad, CA, USA). The purified
total RNA was eluted in 90 μL elution buffer and stored
in three aliquots at −80 °C until further analysis. RNA
quantity and purity was assessed by the NanodropTM
ND-2000 Spectrophotometer (Thermo Fisher Scientific,
Wilmington, DE, USA).
Haematological analysis
The mixed K3EDTA blood tubes (Greiner Bio-One Ltd.,
Stonehouse, UK) was tested on the Sysmex XT-2000i
(Sysmex, Norderstedt, Germany) for the MDS and ATS
elite rowers samples, or the Advia 2120i system (Sie-
mens, Worldwide) for the ATS elite runners samples.
Fig. 2 MDS experimental design. B: baseline; D: during rHuEpo administration; P: post rHuEpo administration
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Standard haematological parameters were measured (i.e.
haemoglobin, HGB; haematocrit, HCT; and reticulocyte
percent, RET%). These samples were measured in
accordance with the WADA Athlete Biological Passport
Operating Guidelines (version 4.0, 2013) [25]. The blood
data was analysed using R lme4 (for applying the linear
model) [26, 27] and phia (for post-hoc interaction
analysis) [28] packages using a mixed design, with two
within-subject variables (the rHuEpo/placebo trial and/
or time covariates) as the fixed factors and subject as the
random factor, in the MDS and ATS, respectively.
Significance level was adjusted using the holm-
bonferroni method.
QuantiGene Plex experiment and data analysis
Two hundred nanogram RNA was run in duplicate for
quantification of the 45 selected RNA targets and 5 ref-
erence genes (ACTB, ACTR10, MRFAP1, PPIB and
RAB11A) in subjects participating in the MDS and ATS,
using the QuantiGene Plex Assay (Affymetrix, Santa
Clara, CA, USA). The resulting fluorescence signal was
measured on the MAGPIX (Luminex, Austin, TX, USA).
The median fluorescence intensity (MFI) values were
viewed and exported from the xPonent software
(Luminex, Austin, TX, USA) for statistical analysis. The
MFI data was background subtracted and normalised to
the geometric mean of the five reference genes. The
coefficient of variation (CV) for assay precision was cal-
culated using the duplicated samples. The “limma” func-
tion implemented in the R limma package [29] was used
to perform the differential expression analysis based on
the adjusted and log2 transformed data. Gene expression
values were compared to the averaged baseline or the
baseline in the MDS (i.e. in the rHuEpo and placebo
groups, respectively), MDS exercise samples (i.e. post vs.
pre exercise as well as before-after treatment compari-
sons in the rHuEpo and placebo groups, respectively)
and ATS (i.e. in the altitude and control groups, respect-
ively), where appropriate. Gene expression changes over
time were also examined in rHuEpo vs. placebo in the
MDS and MDS exercise samples and in altitude vs. con-
trol in the elite runners. Transcripts expression exceed-
ing a FDR [30] < 0.05 and a 1.5 fold-change were
considered meaningful in the current context.
Adaptive model analysis of blood and molecular
signatures
In the MDS, the adaptive Bayesian model was applied
on the two primary markers (i.e. HGB and the stimula-
tion index OFF-score) of the haematological module of
the ABP. Parameters of the model, including within- and
between-subject components of variance, were chosen
to represent a modal population of Caucasian male
athletes aged 20–40 yrs. [31]. The data were analysed by
an investigator without knowing whether the profile was
obtained from a rHuEpo or placebo sample. Following
the unblinding, sensitivity was calculated based on the
portion of samples in the rHuEpo group that produced
at least one atypical value out of individual limits (i.e.
true positives/size of the rHuEpo group), and specificity
was calculated given the portion of samples in the pla-
cebo group that presented no atypical value out of indi-
vidual limits (i.e. true negatives/size of placebo group).
For 41 of the 45 transcripts, within- and between-
subject variances were estimated using the analysis of
variance on the placebo data of log2 expression with
subject as a random effect. A leave-one-out cross-
validation procedure was used to minimise overfitting.
The adaptive model was applied assuming universal
components of variance and normality in the within-
subject variations of the transcripts. A specificity level of
99% was chosen for all reference ranges returned by the
adaptive model. Area under the Receiving Operating
Characteristic (ROC) curve was computed on the
percentiles at which HGB, OFF-score and all transcript
sequences were falling in the distribution of sequences
as returned by the adaptive model.
Results
Samples available for analysis
In the MDS, 343 out of 364 samples (i.e. 14 subjects × 2
trials × 13 time points), including 174 and 169 samples
following rHuEpo and placebo injections, respectively,
were collected and analysed using the QuantiGene Plex
Assay (Affymetrix, Santa Clara, CA, USA). The average
CV was 10.6% across all samples analysed (vs. 15%
typical CV of the QuantiGene Plex Assay [32]). 171
(98.3% of 174) and 163 (96.4% of 169) samples under
rHuEpo and placebo administration were available for
the haematological analysis, respectively. 164 of 168
MDS exercise samples (i.e. 14 subjects × 2 trials × 6
exercise samples) were available for the QuantiGene Plex
2.0 Assay (Affymetrix, Santa Clara, CA, USA) analysis.
The average CV was 16% across these samples. In the
ATS elite runners, 66 of 72 samples (i.e. 12 subjects × 6
time points) obtained following altitude training and 22
of 27 samples (i.e. 9 subjects × 3 time points) obtained
following sea-level training were processed using the
QuantiGene Plex 2.0 Assay (Affymetrix, Santa Clara,
CA, USA). 48 and 23 samples were available for HGB/
HCT analysis in the elite runners and controls, and 37
and 21 samples for RET% calculation in the elite runners
and controls, respectively. In the ATS elite rowers, 28
samples (i.e. 4 subjects × 7 time points) were available
for the haematological and gene expression analyses.
The average CVs were 8.4% and 9.8% across the samples
from elite runners and rowers, respectively. Forty-one of
the 45 transcripts exceeding the assay limit of detection
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were available for gene expression analysis in the MDS
and ATS and 35 for MDS exercise-induced gene expres-
sion analysis, respectively.
Haematological analysis
In the MDS, both HGB concentration and HCT
percentage were gradually increased throughout the
rHuEpo administration relative to the baseline values
and reached the maximum one week after the last injec-
tion (Holm-Bonferroni adjusted p < 0.05) (Fig. 3). RET%
increased rapidly after the first injection and remained
significantly elevated for 4 weeks (Holm-Bonferroni
adjusted p < 0.05) (Fig. 3). The RET% was significantly
lower compared to the baseline values (Holm-Bonferroni
adjusted p < 0.05) throughout the post-rHuEpo phase
(Fig. 3). The OFF-score showed an increasing trend
during rHuEpo administration and significantly
increased throughout the post phase (Holm-Bonferroni
adjusted p < 0.05) (Fig. 3). No significant differences over
time were found for the HGB and HCT parameters
compared to baseline values in the placebo trial in the
MDS, however, RET% were significantly increased at
During 5 and Post 2 and while OFF-scores were signifi-
cantly lower at During 4–7 and Post 1,2 in the placebo
trial (Holm-Bonferroni adjusted p < 0.05). When
comparing the blood data between the rHuEpo and pla-
cebo groups, similar trends and findings were obtained
to those observed in the rHuEpo group. Haematological
analysis in the ATS elite runners revealed a significant
decrease in HGB during altitude (approximately 10 days
at altitude), a significant increase in RET% and a signifi-
cant decrease in OFF-scores post 2 weeks of sea-level
training (Holm-Bonferroni adjusted p = 0.036, 0.02 and
0.002, respectively, see Additional files 2 and 3). No
other significant differences were observed in these
blood parameters over time at available time points
(compared to the baseline), neither in the altitude group
nor in the control group of the ATS elite runners
(Holm-Bonferroni adjusted p > 0.05). Similarly, in the
ATS elite rowers, no significant changes were observed
over time in comparison to baseline values for the four
haematological markers (see Additional file 4).
Gene expression analysis
In the group of subjects following the rHuEpo injection
in the MDS, differentially expressed genes were firstly
selected based on the moderated F-statistic computed by
the “eBayes” function implemented in the R limma pack-
age. Thirty-six out of the 41 genes exceeded the overall
test of significance at the FDR adjusted p of 0.05. Of
Fig. 3 Haemoglobin concentration, haematocrit (%), reticulocytes (%) and OFF-score in subjects taken rHuEpo in the MDS. Data is displayed by
means with corresponding individual changes over time. B: baseline; D: during rHuEpo administration; P: post rHuEpo administration. The number
in the parentheses indicates the blood sampling day relative to the day of the first rHuEpo injection (i.e. B3)
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these 36 genes, 23 were selected when individual con-
trasts in gene expression revealed non-zero differences
seven days after the last rHuEpo injection (i.e. Post 1) at
FDR < 0.05. Subsequently, 17 of the 23 genes were found
significantly altered in expression, exceeding a fold-
change of 1.5 (FDR < 0.05), ten days (i.e. During 2) after
the first injection. Among the 17 genes, 11 were consist-
ently over-expressed from During 2 (Day 10) to During
5 (Day 31) and were then under-expressed throughout
the post-administration stage, i.e. Post 1 (Day 52) to Post
3 (Day 66) (FDR < 0.05 with 1.5 fold-change threshold)
(Table 1). Nine of the 11 genes, ALAS2, BCL2L1,
DCAF12, EPB42, GMPR, SELENBP1, SLC4A1, TMOD1
and TRIM58 (Table 1 and Additional file 5), were com-
mon with the 34 transcripts previously identified and
validated [23]. None of the 41 genes were differentially
expressed in the placebo group over time (FDR > 0.15).
When comparing the levels of gene expression in the
rHuEpo group with that in the placebo group, 24 of the
41 genes were down-regulated at Post 1–3 (FDR < 0.05
with 1.5 fold-change threshold) (Table 2), overlapping
the 9 genes aforementioned and no genes were differen-
tially expressed in the “During” stage between the
rHuEpo group and the placebo group (FDR > 0.17).
Seven genes (1 up-, CD247 and 6 down-regulated,
BPGM, FECH, SNCA, STRADB, TRIM58 and YOD1) of
the 35 were significantly altered immediately following
10 sprints of 10 s compared to baseline (i.e. pre exercise)
before the rHuEpo injection and 2 genes (1 up-, CD247
and 1 down-regulated, LOC100130562) after the last
rHuEpo injection (FDR < 0.05 with 1.5 fold-change
threshold) (see Additional file 6). One (up-regulated,
CD247) and 16 (1 up-, CD247 and 15 down-regulated,
ADIPOR1, BCL2L1, BPGM, CA1, DCAF12, FAM46C,
FBXO7, FECH, OSBP2, SNCA, STRADB, TRIM58,
UBXN6, YBX3 and YOD1) genes of the 35 were found
significantly altered immediately after the repeated sprint
tests in comparison to pre-exercise gene expression
before and after the placebo injection, respectively (FDR <
0.05 with 1.5 fold-change threshold) (see Additional file 6).
No significant changes were found post 30 min of exercise
vs. pre exercise in either rHuEpo or placebo trials. When
Table 1 11 genes differentially expressed at During 2 to 5 and throughout the post rHuEpo administration in the MDS
Gene During
2
During
3
During
4
During
5
Post 1 Post 2 Post 3 During
2
During
3
During
4
During
5
Post 1 Post 2 Post 3
Log2 FC FC
ALAS2 0.86 0.95 0.80 0.70 −0.82 −1.32 −1.18 1.81 1.93 1.75 1.63 −1.77 −2.50 −2.26
BCL2L1 0.71 0.81 0.79 0.69 −0.67 −0.88 −0.89 1.63 1.75 1.73 1.61 −1.59 −1.84 −1.85
DCAF12 0.60 0.78 0.73 0.66 −0.59 −0.90 −0.89 1.52 1.72 1.66 1.58 −1.50 −1.87 −1.86
EPB42 0.86 0.98 0.88 0.76 −0.89 −1.25 −1.08 1.82 1.97 1.84 1.69 −1.85 −2.37 −2.11
GMPR 0.81 0.94 0.79 0.68 −0.72 −0.94 −0.84 1.75 1.92 1.73 1.60 −1.65 −1.92 −1.79
OSBP2 0.96 1.08 1.05 1.00 −0.89 −1.16 −1.03 1.95 2.12 2.07 2.00 −1.85 −2.23 −2.04
SELENBP1 0.98 1.09 0.97 0.83 −0.90 −1.19 −1.05 1.97 2.13 1.96 1.77 −1.87 −2.29 −2.07
SLC4A1 0.89 1.08 0.96 0.82 −0.87 −1.18 −1.10 1.86 2.12 1.94 1.77 −1.83 −2.26 −2.14
TMOD1 0.65 0.89 0.76 0.61 −0.71 −1.06 −1.00 1.57 1.85 1.70 1.53 −1.64 −2.08 −2.01
TNS1 0.84 1.10 0.98 0.87 −0.94 −1.22 −1.10 1.79 2.14 1.97 1.83 −1.91 −2.34 −2.14
TRIM58 0.73 0.82 0.72 0.67 −0.74 −0.94 −0.97 1.66 1.76 1.65 1.59 −1.67 −1.92 −1.96
Uncorrected P val. FDR
ALAS2 0.00181 0.00055 0.00337 0.01011 0.00274 0.000003 0.00002 0.00778 0.00173 0.00767 0.02030 0.01443 0.00006 0.00008
BCL2L1 0.00180 0.00038 0.00048 0.00230 0.00317 0.00013 0.00009 0.00778 0.00171 0.00367 0.01678 0.01443 0.00031 0.00025
DCAF12 0.00912 0.00072 0.00157 0.00434 0.01090 0.00014 0.00012 0.01558 0.00193 0.00430 0.01678 0.02482 0.00031 0.00031
EPB42 0.00488 0.00139 0.00416 0.01333 0.00378 0.00007 0.00045 0.01052 0.00300 0.00877 0.02277 0.01551 0.00022 0.00092
GMPR 0.00165 0.00026 0.00200 0.00793 0.00479 0.00034 0.00110 0.00778 0.00152 0.00492 0.01835 0.01679 0.00064 0.00196
OSBP2 0.00024 0.00004 0.00006 0.00014 0.00071 0.00002 0.00009 0.00778 0.00079 0.00252 0.00591 0.01443 0.00008 0.00025
SELENBP1 0.00118 0.00030 0.00129 0.00603 0.00283 0.00011 0.00053 0.00778 0.00152 0.00407 0.01835 0.01443 0.00030 0.00103
SLC4A1 0.00848 0.00148 0.00478 0.01499 0.01016 0.00069 0.00126 0.01511 0.00303 0.00933 0.02458 0.02451 0.00124 0.00215
TMOD1 0.00520 0.00015 0.00105 0.00849 0.00218 0.000010 0.00002 0.01052 0.00152 0.00388 0.01835 0.01443 0.00008 0.00008
TNS1 0.00531 0.00026 0.00114 0.00376 0.00181 0.00007 0.00027 0.01052 0.00152 0.00388 0.01678 0.01443 0.00022 0.00058
TRIM58 0.00190 0.00051 0.00204 0.00450 0.00172 0.00009 0.00004 0.00778 0.00173 0.00492 0.01678 0.01443 0.00026 0.00014
Log2 FC log2 transformed fold-change, FC fold-change, FDR false discovery rate adjusted significance
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comparing exercise gene expression changes before-after
rHuEpo or placebo injections, no differences were ob-
served, neither immediately nor 30 min post exercise
(FDR > 0.93). Furthermore, there were no significant
changes in transcription following exercise when compar-
ing the rHuEpo group vs. the placebo group (FDR > 0.70).
In the 12 elite runners, 28 out of the 41 genes
exceeded an overall F-test significance at the FDR ad-
justed p of 0.05 following altitude training (see Add-
itional file 7, green section). The remaining 13 genes
demonstrated non-significant changes in gene expres-
sion (F-test FDR > 0.05; see Additional file 7). Following
pairwise comparisons, trends towards 5% FDR were ob-
served for 20 genes (out of the 28) down-regulated one
week after returning from altitude and 13 genes (out of
the 20) were up-regulated approximately 10 days after
reaching altitude (FDR > 0.059 and 0.064, respectively;
see Additional file 7). Of the 13 genes, ALAS2, BCL2L1,
DCAF12, SLC4A1 TMOD1 and TRIM58 (FDR > 0.059
with the fold-change varied from 1.39 to 1.63, see
Additional files 7 and 8) were in common with the 9
MDS genes. In the elite runners, no genes were differen-
tially expressed in the control group or responded differ-
ently over time in the altitude group relative to the
control group post 2 and 4 weeks of altitude or sea-level
training (FDR > 0.20 and 0.60, respectively). In the 4 elite
rowers, no genes responded differently following 2-week
altitude in conjunction with adaptation to simulated alti-
tude when compared with the averaged baseline.
Adaptive model analysis
In the MDS, using 13 samples per subject collected at
weekly intervals including 3 weekly samples post-
supplementation, rHuEpo use was identified in 13 out of
14 subjects and without any false positives, for a specifi-
city of 99% in the ABP using the haematological markers
of HGB and OFF-score (Table 3); 41 out of the 45 were
amenable to analysis using the adaptive model. A higher
between- compared to within-subject variability was ob-
served across the examined genes (averaged variance:
Table 2 24 genes responded differently (significantly down-regulated over Post 1, 2, 3) in the rHuEpo group relative to the placebo
group in the MDS
Log2 FC FC Uncorrected P val. FDR
Gene Post 1 Post 2 Post 3 Post 1 Post 2 Post 3 Post 1 Post 2 Post 3 Post 1 Post 2 Post 3
ADIPOR1 −0.69 −1.17 −1.02 −1.61 −2.24 −2.03 0.00669 0.00001 0.00007 0.01958 0.00009 0.00048
ALAS2 −1.10 −1.78 −1.55 −2.14 −3.43 −2.93 0.00504 0.00001 0.00008 0.01720 0.00009 0.00048
BCL2L1 −0.97 −1.29 −1.12 −1.96 −2.44 −2.18 0.00269 0.00010 0.00050 0.01720 0.00026 0.00172
BPGM −0.72 −1.11 −1.04 −1.64 −2.16 −2.05 0.00417 0.00002 0.00004 0.01720 0.00010 0.00048
CA1 −0.82 −1.28 −1.12 −1.76 −2.42 −2.18 0.01519 0.00022 0.00090 0.02967 0.00044 0.00223
CSDA −0.80 −1.25 −1.12 −1.75 −2.39 −2.18 0.00791 0.00005 0.00022 0.01959 0.00020 0.00088
DCAF12 −0.77 −1.24 −1.05 −1.70 −2.36 −2.07 0.01941 0.00024 0.00144 0.03351 0.00045 0.00282
EPB42 −1.30 −1.76 −1.44 −2.47 −3.39 −2.72 0.00286 0.00009 0.00097 0.01720 0.00025 0.00223
FAM46C −0.66 −1.12 −0.98 −1.58 −2.17 −1.98 0.00462 0.00000 0.00003 0.01720 0.00009 0.00048
FBXO7 −0.64 −1.02 −0.94 −1.56 −2.03 −1.91 0.00792 0.00003 0.00011 0.01959 0.00014 0.00049
FECH −0.78 −1.20 −1.13 −1.72 −2.30 −2.18 0.00545 0.00003 0.00007 0.01720 0.00014 0.00048
GMPR −1.06 −1.39 −1.11 −2.08 −2.62 −2.16 0.00391 0.00022 0.00249 0.01720 0.00044 0.00465
GUK1 −0.77 −1.26 −1.05 −1.71 −2.40 −2.07 0.01462 0.00010 0.00098 0.02967 0.00026 0.00223
KRT1 −1.16 −1.53 −1.22 −2.24 −2.89 −2.33 0.00181 0.00006 0.00110 0.01720 0.00021 0.00236
OSBP2 −0.78 −1.13 −0.99 −1.72 −2.19 −1.99 0.00820 0.00020 0.00086 0.01959 0.00043 0.00223
SELENBP1 −1.28 −1.68 −1.39 −2.43 −3.21 −2.62 0.00295 0.00014 0.00124 0.01720 0.00033 0.00254
SLC4A1 −1.27 −1.60 −1.37 −2.42 −3.03 −2.58 0.00860 0.00123 0.00476 0.01959 0.00209 0.00813
SNCA −0.84 −1.47 −1.28 −1.79 −2.77 −2.42 0.00952 0.00001 0.00009 0.02054 0.00009 0.00048
STRADB −0.85 −1.36 −1.20 −1.80 −2.56 −2.30 0.00438 0.00001 0.00006 0.01720 0.00009 0.00048
TMOD1 −0.99 −1.43 −1.22 −1.98 −2.69 −2.33 0.00303 0.00003 0.00025 0.01720 0.00014 0.00094
TNS1 −1.26 −1.63 −1.26 −2.40 −3.10 −2.39 0.00318 0.00020 0.00330 0.01720 0.00043 0.00589
TRIM58 −0.93 −1.25 −1.15 −1.91 −2.38 −2.22 0.00536 0.00027 0.00061 0.01720 0.00049 0.00181
UBXN6 −0.71 −1.23 −1.05 −1.64 −2.35 −2.07 0.01962 0.00009 0.00062 0.03351 0.00025 0.00181
YOD1 −0.59 −1.10 −1.04 −1.50 −2.14 −2.05 0.01831 0.00002 0.00004 0.03351 0.00011 0.00048
Log2 FC log2 transformed fold-change, FC fold-change, FDR false discovery rate adjusted significance
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0.21 vs. 0.13; Table 3). Fifteen transcripts showed a
sensitivity of ≥93% and a specificity of ≥71%, with the
ROC area ≥ 0.92 (Table 3). BCL2L1 and CSDA were the
genes with the highest sensitivity (93%) and specificity
(93%), with the ROC area of 0.96 and 0.98, respectively
(Table 3). In the MDS differential gene expression
analysis, the BCL2L1 gene was significantly expressed at
During 2–5 and Post 1–3 in the rHuEpo group (Table 1,
FDR < 0.05 and fold-change >1.5) and at Post 1–3 in the
rHuEpo group vs. the placebo group (Table 2, FDR <
0.05 and fold-change >1.5); the CSDA gene was signifi-
cantly down-regulated at Post 1–3 (FDR < 0.05 and fold-
change >1.5) in the rHuEpo group vs. the placebo group
(Table 2). HGB concentration (g·L−1), OFF-score and
gene expression changes (of the 41 transcripts) across 28
subjects (14 subjects × 2 trials) obtained from the
adaptive model and ROC curves are provided in
Additional files 9, 10 and 11.
Discussion
Twenty-four of the 41 genes showed a significant and long
lasting down-regulation following the last rHuEpo injec-
tion in the MDS given a fold-change of 1.5 and 5% FDR
spanning the post rHuEpo stage for 3 weeks (Table 2).
This prolonged detection window in terms of the long
lasting effect and the stability of the gene markers col-
lected using the Tempus™ Blood RNA method is promis-
ing and will undoubtedly improve the efficiency of
rHuEpo detection given the substantially shorter detection
duration of 36 h for improved analytical quality when
using the current haematological markers [8]. Fifteen of
the 24 genes showed a high sensitivity (≥ 93%) with speci-
ficity equal to or above 71% (Table 3). Particularly, the
BCL2L1 and CSDA exhibited the highest sensitivity (93%)
and specificity (93%) amongst the 15 genes (Table 3). The
majority of the 9 genes that were consistently expressed
during and post rHuEpo in the MDS rHuEpo group,
namely ALAS2, BCL2L1, DCAF12, EPB42, GMPR,
SELENBP1, SLC4A1, TMOD1 and TRIM58 were associ-
ated with erythrocyte membrane structure and red blood
cell metabolism; these 9 genes were in common with the
34 transcripts previously identified and validated [23],
while 7 of the 9 genes were in common with the 15 genes
showing high sensitivity and specificity. The major spliced
mRNA isoform of the ALAS2 has significant impact on
erythroid heme biogenesis and hemogobin formation [33].
Erythrocyte survival is suppressed by the BH3 peptide
through antagonizing Bcl-X(L) [34]. EPB42 deficiency
causes hereditary spherocytosis, leading to chronic
haemolytic anemia with abnormally shaped erythrocytes
[35]. The EPB42 may be involved in the regulation of
erythrocyte shape and mechanical properties [36]. The
SELENBP1 is thought to play a role in rapid cell out-
growth by determining the direction of the outgrowth and
Table 3 The adaptive model analysis summarising the within-
and between-subject variances, sensitivity, specificity and ROC
area for the HGB concentration, OFF-score and 41 transcripts
analysed in the MDS
Mean Within-
subject
variance
Between-
subject
variance
Sensitivity
(%)
Specificity
(%)
ROC
area
HGB (g·L -1) 150 29 36 79 93 0.87
OFF-score 92 51 62 93 93 0.93
ADIPOR1 3.33 0.098 0.085 86 79 0.97
ALAS2 3.09 0.204 0.282 100 79 0.97
BCL2L1 1.33 0.159 0.202 93 93 0.96
BPGM 2.74 0.107 0.087 93 71 0.98
CA1 1.28 0.159 0.190 93 79 0.97
CCR7 −0.15 0.092 0.155 29 93 0.78
CD247 −0.66 0.059 0.046 43 71 0.62
CD3D 0.30 0.061 0.048 43 64 0.63
CSDA 2.68 0.136 0.150 93 93 0.98
DCAF12 2.18 0.146 0.198 93 79 0.98
EEF1D 1.75 0.026 0.027 43 64 0.63
EPB42 −0.91 0.243 0.448 93 86 0.96
FAM46C 3.74 0.083 0.061 93 79 0.95
FBXO7 3.54 0.079 0.075 79 79 0.92
FECH 1.34 0.142 0.119 86 71 0.95
GMPR 0.23 0.181 0.281 86 86 0.93
GUK1 0.51 0.130 0.228 86 79 0.95
GYPE −4.87 0.145 0.282 79 93 0.92
HBD 0.20 0.243 0.885 64 64 0.95
KRT1 −1.31 0.327 1.229 86 71 0.86
LEF1 0.37 0.083 0.129 36 93 0.68
LOC100130562 2.78 0.032 0.027 50 71 0.63
LOC286444 0.73 0.034 0.049 50 79 0.69
MIF −0.15 0.043 0.021 36 71 0.62
OSBP2 0.61 0.205 0.206 93 79 0.97
PITHD1 0.20 0.125 0.183 86 86 0.92
RBM38 0.44 0.150 0.566 79 79 0.89
RNF213 0.76 0.102 0.062 36 79 0.42
SELENBP1 0.63 0.240 0.401 93 79 0.92
SGK223 −2.81 0.064 0.042 36 79 0.60
SKAP1 −1.52 0.055 0.052 43 79 0.61
SLC4A1 1.36 0.213 0.595 93 86 0.96
SNCA 0.87 0.172 0.154 86 71 0.96
STRADB 2.29 0.136 0.145 93 86 0.99
TMOD1 −0.57 0.188 0.163 93 71 0.95
TNS1 −2.05 0.234 0.306 93 86 0.96
TPRA1 −2.43 0.011 0.010 50 79 0.67
TRIM58 2.23 0.156 0.199 86 71 0.98
UBXN6 2.06 0.107 0.209 93 71 0.98
VEGFB −1.62 0.045 0.039 57 64 0.67
YOD1 1.48 0.137 0.050 71 71 0.90
ROC receiving operating characteristic
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the synthesis of actin filaments [37]. There are two struc-
turally and functionally distinct versions of the protein
encoded by the SLC4A1 gene – the N-terminal 40 kDa
cytoplasmic domain attaches to the red cell skeleton by
binding ankyrin to maintain the structure of red blood
cells and the C-terminal 50 kDa membrane domain is re-
sponsible for the transport of anions, by facilitating the ex-
change of chloride and bicarbonate across the plasma
membrane of erythrocytes [38–40]. The TMOD1 protein
also influences the structure of the erythrocyte mem-
brane skeleton by regulating tropomyosin [41]. The
GMPR gene is mapped to chromosome 6p23 [42] and
maintains the intracellular balance of guanine and ad-
enine nucleotides [43]. It was previously reported that
the human red cell glucose-6-phosphate dehydrogenase
is encoded by the chromosome 6- and chromosome X-
encoded genes [44] but subsequently disproved by
other studies [45, 46]. The DCAF12 and TRIM58 as
well as CSDA genes are associated with terminal eryth-
roid differentiation, red blood cell count and red blood
cell interactome networks, respectively [47–49]. As
stated previously, 5 genes (i.e. PFN1, C13orf15, TSTA3,
RPL41 and TOMM40) were identified by Varlet-Marie
et al. using SAGE following administration of the
erythropoiesis-stimulating agent (ESA) darbepoetin
alpha and high doses and microdoses of rHuEpo [19].
However, none of these genes overlapped with the
molecular signature of rHuEpo doping identified and
validated in our previous and current studies. Differ-
ences in study design including the specific drugs, drug
administration methods, sample size and detection
platforms, are all likely factors contributing to these re-
sults, emphasising further the need for rigorous replica-
tion of any markers identified in a single study.
The identification of a similar panel of genes associ-
ated with the structure and function of red blood cells
identified in the present study and those of other clinical
groups (see ref. [33–49]) is encouraging and should as-
sist the development of targeted therapy to treat patients
with blood disorders. There are widespread applications
utilising rHuEpo in clinical settings such as the treat-
ment of patients with anaemia of chronic renal disease,
improving quality of life in cancer patients and minimis-
ing the transfusion requirement [50], but not all patients
respond effectively to treatment with rHuEpo. The tran-
scriptomic markers identified in healthy individuals
administered with rHuEpo in our previous and current
studies represent useful targets to investigate the signal
transduction pathways activated by erythropoietin and
its receptor for improved therapeutic use of ESA and
rHuEpo. With reference to anti-doping, the whole-blood
trancriptomic markers discovered reflect closely the
RET% changes over time (Fig. 3). This is consistent with
the finding that a large amount of mRNA species in
whole blood originate from reticulocytes, evidenced by
the separate clustering of whole blood samples treated
with RNase H and leukocyte samples in microarray ana-
lysis [51]. New approaches that are able to interrogate
the whole transcriptome with improved dynamic range
for adequate quantification (e.g. RNA-seq) and prefera-
bly in leucocytes populations in a sufficient number of
participants are warranted in future anti-doping
transcriptomic studies and especially those involving the
manipulation of red blood cells to improve further the
detection of blood doping using molecular markers.
Approaches enabling the interrogations of whole gen-
ome, transcriptome and metabolome have the increased
capacity to measure rapidly and in the near future, inex-
pensively a large number of molecular signatures, which
will collectively aid the decision making during identify-
ing and differentiating numerous doping substances and
methods by ABP experts when reviewing passports. For
example, one of the transcripts validated in the present
study is the BPGM gene (Table 2), encoding the 2–3
BPG. It is well known that blood doping can affect 2–3
BPG metabolism and is therefore closely monitored by
the WADA ABP Expert Panel. In addition, the only sub-
ject evading detection by the haematological model of
ABP in the present study (see Additional files 9 and 10,
subject R) had a low mean cell volume and mean cell
haemoglobin, indicating iron deficiency or a defect in
iron metabolism and particularly that the subject partici-
pated in the present study is non-responsive to iron sup-
plementation. However, 25 of the 41 genes included in
the adaptive model analysis identified rHuEpo use in the
same subject (see Additional file 11, subject 9). This
illustrates the need for a holistic approach to drug detec-
tion; one based on the inclusion of a variety of parame-
ters that provide information on related pathways and
metabolism (e.g. iron, transferring and total iron binding
capacity). Notably, the large-scale omics studies
combined with the ABP are anticipated to be able to
dramatically improve doping detection. It is also import-
ant to note that the potential for the validated tran-
scripts in the present study to identify the rHuEpo use is
high both when the transcripts are used alone (Tables 1
and 2; 24 genes exceeding a fold-change of 1.5 at 5%
FDR post rHuEpo injections) or in combination with the
current ABP (Table 3; 20 genes with a ROC area > 0.95),
emphasising the need to understand erythropoiesis using
a systems biology approach.
The CD247 gene was significantly up-regulated
exceeding a fold-change of 1.5 at 5% FDR immediately
following exercise when compared to the baseline before
and after rHuEpo/placebo, respectively; but this response
rapidly subsided 30 min after exercise. The CD247
encodes the T-cell receptor zeta, which is a component
of the T-cell receptor-CD3 complex [52]. Low expression
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of the gene may relate to impaired immune response
[53, 54]. This current observation is in line with previous
studies indicating acute inflammatory response following
acute resistance exercise [55, 56] and the subsequent
anti-inflammatory response is to prevent the develop-
ment of chronic inflammation [21, 57]. Six and fifteen
genes were significantly down-regulated (6 is included in
the 15) immediately following exercise before rHuEpo
and after placebo, respectively (FDR < 0.05 and fold-
change >1.5). Among these genes, only TRIM58 overlaps
the 9 MDS genes. TRIM58 specifically expresses during
late erythroid maturation, coinciding with enucleation
and dynein loss [58]. The suppression of TRIM58 relates
to reduced enucleation [58]. TRIM58 gene polymor-
phisms associate with the circulating erythrocyte size
and number [48, 59]. Previous studies reported an
increased number of leukocytes immediately following
heavy exercise [21, 22], whereas the reduced level of
TRIM58 following the repeated sprint test in the present
study may reflect reduced proportions of reticulocytes in
accordance with previous research [58]. This modified
Wingate test did not reveal significant gene expression
changes using the 35 transcripts when comparing before
with after rHuEpo/placebo, or rHuEpo vs. placebo.
These results, although preliminary, argue against exer-
cise/training being a confounder as all gene expression
alterations post strenuous exercise were restored after
30 min and well within the two hours stipulated by
WADA before a blood sample can be obtained for anti-
doping purposes [60]. Nevertheless, the explicit role of
exercise needs to be further investigated not only in
whole blood but also peripheral blood cells in order to
better understand the molecular adaptations to both
acute and chronic exercise (i.e. exercise training) and
avoid confounding the analysis.
Previous studies have shown that short or prolonged
residency at high altitude stimulates the secretion of Epo
from the kidney [61–64]. For example, elevated levels of
Epo are detected as early as 8 h after arrival at high alti-
tude and reaches a peak 24 h after arrival [61]. These
higher levels of Epo are also maintained throughout a
period of high altitude exposure (e.g., ranging from
11 days to 4 weeks at approximately 3500 m or above
[61, 64]). In the present ATS, 13 out of the 41 genes
failed to show statistically significant changes at the
transcriptional level following approximately 2-week
training at moderate altitude in 12 elite runners given a
F-test FDR > 0.05. Six of the remaining 28 genes that
tended to be stimulated by altitude were in common
with the 9 MDS genes (FDR > 0.059 with the fold-
change varied from 1.39 to 1.63 during and after one
week of altitude training; see Additional files 7 and 8).
Among these 6 genes, SLC4A1 showed a tendency to-
wards a 1.63-fold down-regulation (FDR = ~ 0.059) one
week after altitude training and TMOD1 a tendency for
a 1.50-fold up-regulation (FDR = ~ 0.064) after ten days
of altitude exposure; none of the other genes exceeded
the 1.5 fold-change cut-off (FDR > 0.059) (see Additional
file 7). In comparison, in the MDS rHuEpo group,
DCAF12 showed a least 1.52-fold up-regulation (FDR = ~
0.016) ten days after the first rHuEpo injection (i.e. Dur-
ing 2) and this level of expression was maintained for
4 weeks for all 6 genes (i.e. During 2–5, FDR < 0.05,
Table 1). In addition, there was at least 1.50-fold down-
regulation (FDR = ~ 0.025) in DCAF12 one week after
the last rHuEpo injection (i.e. Post 1) with this level of
change lasting throughout the 3 weeks for all 6 genes
(i.e. Post 1–3, FDR < 0.05, Table 1), with majority of the
6 genes approaching or exceeding a 2 fold-change at the
post rHuEpo stage (Table 1). There was also a more pro-
nounced gene expression response in these 6 genes post
rHuEpo administration compared to the placebo group
(FDR < 0.05, Table 2), with an approximate 2.5 fold-
change in ALAS2, SLC4A1 and TMOD1 2 and 3 weeks
after the last injections (i.e. Post 2, 3, Table 2). As stated
previously, the observed patterns of change in gene
expression in MDS reflect closely the RET% changes
over time (Fig. 3). In comparison, haematological ana-
lysis in the ATS elite runners revealed a small but sig-
nificant decrease in HGB during altitude (approximately
10 days at altitude) (FDR = 0.036, see Additional file 2).
No genes were differentially expressed in the control
group or responded differently over time in the altitude
group relative to the control group and this trend was in
general agreement with the haematological results that
showed no change over time despite exposure to alti-
tude. The relatively long lasting effects and high magni-
tude of changes of the validated transcriptional markers
of rHuEpo compared with the gene expression changes
of the same markers (i.e. the 6 genes) in the ATS elite
runners provide strong evidence in favour of applying
such markers, alongside current anti-doping strategies to
detect blood doping. The finding of no change in gene
expression or in the measured haematological variables
in the four elite rowers most likely reflects the limited
exposure to moderate altitude, the small sample size and
the typical inter-individual variation (see additional file 4).
An altitude study with extended exposure (for 4 weeks at
least) at high altitude (~ 3000 m) involving the analysis of
both whole blood and peripheral blood for omics marker
identification is required to better understand the molecu-
lar adaptations to altitude as compared to blood doping.
Only then can the molecular response to altitude training
be excluded, or if needed, integrated in the ABP along
with other confounders to detect blood doping. Assessing
and determining other confounding variables influencing
the biological and analytical variability of the gene markers
through altered erythropoiesis presents a critical next step
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to enhance the specificity and sensitivity of current ABP
for unbiased detection of blood doping in conjunction
with a systems biology approach.
Conclusions
In conclusion, several human whole-blood transcriptional
signatures signifying predominantly altered red blood cell
production were identified following rHuEpo injections
ranging from high doses to microdoses. These findings sup-
port the use of molecular markers as potential biomarkers
with an improved detection window and high sensitivity
and specificity for developing the transcriptionally-
enhanced ABP model for detecting blood doping. Collect-
ively, the findings of the present study, interpreted in the
context of the latest omics research, are encouraging and
suggest a systems biology approach combining various
omics signatures from genomics, transcriptomics, proteo-
mics and metabolomics will inevitably provide a deeper
understanding of the effects of erythropoietic stimulating
agents on erythropoiesis with unparalleled potential to
improve current drug detection strategies with particular
reference to blood doping. However, continuous and
rigorous efforts will be required to determine, accommo-
date and possibly eliminate other confounding effects on
blood doping.
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